MedPath

Apomorphine

Generic Name
Apomorphine
Brand Names
Apokyn
Drug Type
Small Molecule
Chemical Formula
C17H17NO2
CAS Number
58-00-4
Unique Ingredient Identifier
N21FAR7B4S
Background

Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.

Apomorphine was granted FDA approval on 20 April 2004.

Indication

Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.

Associated Conditions
Mobility decreased
Clinical Trials
Related News

Infusion of Apomorphine: Long-term Safety Study

Phase 3
Active, not recruiting
Conditions
Idiopathic Parkinson's Disease
Interventions
First Posted Date
2015-01-15
Last Posted Date
2024-04-25
Lead Sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Target Recruit Count
99
Registration Number
NCT02339064
Locations
🇺🇸

Portland VA Medical Center, Portland, Oregon, United States

Treatment of Apomorphine-induced Skin Reactions: a Pilot Study

Phase 2
Terminated
Conditions
Apomorphine-induced Skin Reactions
Parkinson's Disease
Interventions
Device: Massage with a spiky ball
First Posted Date
2014-09-03
Last Posted Date
2024-03-13
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
13
Registration Number
NCT02230930
Locations
🇳🇱

Department of Neurology, Groningen, Netherlands

A Study to Examine APL-130277 in Patients With Parkinson's Disease

Phase 2
Completed
Conditions
Parkinson's Disease
Interventions
First Posted Date
2014-08-29
Last Posted Date
2020-07-30
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
20
Registration Number
NCT02228590
Locations
🇺🇸

Banner Sun Health Research Institute, Sun City, Arizona, United States

🇺🇸

Rocky Mountain Movement Disorders Center, Englewood, Colorado, United States

🇺🇸

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States

and more 1 locations

Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease

Phase 3
Completed
Conditions
Parkinson's Disease
Interventions
Drug: Placebo
First Posted Date
2013-12-09
Last Posted Date
2019-07-08
Lead Sponsor
Britannia Pharmaceuticals Ltd.
Target Recruit Count
107
Registration Number
NCT02006121
Locations
🇦🇹

Medizinische Universität Graz / Univ. Klinik für Neurologie, Graz, Austria

🇳🇱

Universitair Medisch Centrum, Groningen, Netherlands

🇦🇹

Donauspital / SMZ-Ost, Abteilung für Neurologie, Sekretariat (Stock 1, Ebene 4), Vienna, Austria

and more 17 locations

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

Phase 4
Completed
Conditions
Motor Symptoms
Parkinson's Disease
Hypomobility
Akinesia
Delayed Levodopa Onset
Interventions
First Posted Date
2013-01-17
Last Posted Date
2023-08-14
Lead Sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Target Recruit Count
127
Registration Number
NCT01770145
Locations
🇺🇸

Henry Ford West Bloomfield Hospital, Bloomfield Hills, Michigan, United States

🇺🇸

University of Texas Health Science Center, Houston, Department of Neurology, Houston, Texas, United States

🇺🇸

Center for Neurological Care and Research, San Antonio, Texas, United States

and more 9 locations

Apomorphine Effects on Experimental Pain

Early Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2012-12-07
Last Posted Date
2016-09-16
Lead Sponsor
Rambam Health Care Campus
Target Recruit Count
105
Registration Number
NCT01744964
Locations
🇮🇱

Rambam Health Care Campus, Haifa, Israel

Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease

Phase 3
Completed
Conditions
Parkinson's Disease
Interventions
Drug: injection of placebo of apomorphine
Drug: injection of placebo of L-Dopa
First Posted Date
2012-01-05
Last Posted Date
2017-02-23
Lead Sponsor
University Hospital, Toulouse
Target Recruit Count
28
Registration Number
NCT01504178
Locations
🇫🇷

CIC, Purpan Hospital, Toulouse, France

Extended Long-Term Safety Study of KW-6500

Phase 3
Completed
Conditions
Parkinson's Disease
Interventions
First Posted Date
2010-02-05
Last Posted Date
2017-03-15
Lead Sponsor
Kyowa Kirin Co., Ltd.
Target Recruit Count
27
Registration Number
NCT01063621

Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500

Phase 3
Completed
Conditions
Parkinson's Disease
Interventions
Drug: KW-6500 Placebo
First Posted Date
2010-01-28
Last Posted Date
2017-03-03
Lead Sponsor
Kyowa Kirin Co., Ltd.
Target Recruit Count
31
Registration Number
NCT01058291
Locations
🇯🇵

Ehime University Hospital, Toon, Ehime, Japan

Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease

Phase 3
Completed
Conditions
Parkinsons's Disease
Interventions
Drug: Usual dopaminergic per os treatment
First Posted Date
2009-12-24
Last Posted Date
2023-05-24
Lead Sponsor
Rennes University Hospital
Target Recruit Count
21
Registration Number
NCT01039090
Locations
🇫🇷

Rennes University Hospital, Rennes, France

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy